$301 Million is the total value of Stonepine Capital Management, LLC's 23 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 38.1% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
Buy | QUIDELORTHO CORP | $48,118,314 | -6.2% | 658,794 | +6.4% | 15.98% | -13.7% | |
EOLS | Buy | EVOLUS INC | $47,336,097 | +44.5% | 5,179,004 | +14.9% | 15.72% | +33.1% |
Buy | AMYLYX PHARMACEUTICALS INC | $46,065,543 | +90.5% | 2,515,868 | +124.4% | 15.30% | +75.5% | |
ADMA | Buy | ADMA BIOLOGICS INC | $32,593,305 | +0.4% | 9,104,275 | +3.5% | 10.83% | -7.5% |
GLPG | Buy | GALAPAGOS NV-SPON ADRspons adr | $27,727,895 | -0.1% | 802,544 | +17.6% | 9.21% | -8.0% |
New | ALIMERA SCIENCES INC | $12,349,427 | – | 3,983,686 | +100.0% | 4.10% | – | |
Sell | MAXCYTE INC | $11,736,317 | -35.5% | 3,761,640 | -5.2% | 3.90% | -40.6% | |
Buy | XERIS BIOPHARMA HOLDINGS INC | $11,002,592 | -23.6% | 5,915,372 | +7.5% | 3.66% | -29.7% | |
GMDA | Buy | GAMIDA CELL LTD | $8,204,841 | +183.4% | 7,965,865 | +431.1% | 2.73% | +161.1% |
LIFE | Sell | ATYR PHARMA INC | $7,310,066 | -26.9% | 4,626,624 | -0.0% | 2.43% | -32.6% |
SCYX | Sell | SCYNEXIS INC | $6,503,926 | -25.2% | 2,852,599 | -3.2% | 2.16% | -31.1% |
XOMA | Buy | XOMA CORP | $6,151,722 | -6.8% | 436,602 | +25.0% | 2.04% | -14.2% |
XFOR | Buy | X4 PHARMACEUTICALS INC | $5,748,317 | -35.7% | 5,273,685 | +14.5% | 1.91% | -40.7% |
AVIR | Buy | ATEA PHARMACEUTICALS INC | $5,160,000 | +83.4% | 1,720,000 | +128.7% | 1.71% | +68.9% |
RZLT | REZOLUTE INC | $4,055,668 | -33.3% | 3,072,476 | 0.0% | 1.35% | -38.6% | |
TELA | Buy | TELA BIO INC | $3,935,352 | -19.5% | 491,919 | +1.9% | 1.31% | -25.9% |
XGN | Buy | EXAGEN INC | $2,912,448 | -4.3% | 1,203,491 | +14.7% | 0.97% | -11.9% |
New | IO BIOTECH INC | $2,785,184 | – | 1,975,308 | +100.0% | 0.92% | – | |
GOSS | New | GOSSAMER BIO INC | $2,781,056 | – | 3,339,405 | +100.0% | 0.92% | – |
DCTH | Buy | DELCATH SYSTEMS INC | $2,779,272 | +32.5% | 686,240 | +81.2% | 0.92% | +21.9% |
ASRT | New | ASSERTIO HOLDINGS INC | $2,435,064 | – | 951,197 | +100.0% | 0.81% | – |
VNDA | New | VANDA PHARMACEUTICALS INC | $2,064,541 | – | 477,903 | +100.0% | 0.69% | – |
AYTU BIOPHARMA INC | $1,275,396 | +68.8% | 472,369 | 0.0% | 0.42% | +55.3% | ||
CSTL | Exit | CASTLE BIOSCIENCES INC | $0 | – | -91,978 | -100.0% | -0.46% | – |
URGN | Exit | UROGEN PHARMA LTD | $0 | – | -448,508 | -100.0% | -1.67% | – |
Exit | THIRD HARMONIC BIO INC | $0 | – | -2,793,149 | -100.0% | -4.85% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-13
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
CTI Biopharmap Corp. | 24 | Q1 2023 | 14.8% |
APOLLO ENDOSURGERY INC | 23 | Q1 2023 | 15.6% |
XOMA CORP | 20 | Q3 2023 | 5.7% |
Cumberland Pharmaceuticals, Inc. | 19 | Q4 2020 | 7.0% |
Amarin Corp PLC - SPONS ADR | 14 | Q3 2022 | 23.2% |
VANDA PHARMACEUTICALS INC | 14 | Q3 2023 | 20.9% |
BIODELIVERY SCIENCES INTL | 14 | Q1 2020 | 12.9% |
AFFIMED NV | 13 | Q3 2022 | 7.7% |
ALIMERA SCIENCES INC | 13 | Q3 2019 | 4.2% |
VIVEVE MEDICAL INC | 12 | Q2 2019 | 15.3% |
View Stonepine Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
CTI BIOPHARMA CORP | April 13, 2023 | 7,018,046 | 5.3% |
ADMA BIOLOGICS, INC. | February 13, 2023 | 6,940,000 | 3.1% |
Amryt Pharma plc | February 13, 2023 | 31,666,195 | 9.9% |
Apollo Endosurgery, Inc. | February 13, 2023 | 4,351,088 | 9.0% |
Conformis Inc | February 13, 2023 | 748,194 | 9.9% |
Ovid Therapeutics Inc.Sold out | February 13, 2023 | 0 | 0.0% |
Adamas Pharmaceuticals IncSold out | February 14, 2022 | 0 | 0.0% |
CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
Conformis Inc | February 14, 2022 | 14,768,823 | 7.9% |
YUMANITY THERAPEUTICS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Stonepine Capital Management, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
SC 13G/A | 2024-02-13 |
View Stonepine Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.